Literature DB >> 17062703

Basic mechanisms responsible for osteolytic and osteoblastic bone metastases.

Theresa A Guise1, Khalid S Mohammad, Gregory Clines, Elizabeth G Stebbins, Darren H Wong, Linda S Higgins, Robert Vessella, Eva Corey, Susan Padalecki, Larry Suva, John M Chirgwin.   

Abstract

Certain solid tumors metastasize to bone and cause osteolysis and abnormal new bone formation. The respective phenotypes of dysregulated bone destruction and bone formation represent two ends of a spectrum, and most patients will have evidence of both. The mechanisms responsible for tumor growth in bone are complex and involve tumor stimulation of the osteoclast and the osteoblast as well as the response of the bone microenvironment. Furthermore, factors that increase bone resorption, independent of tumor, such as sex steroid deficiency, may contribute to this vicious cycle of tumor growth in bone. This article discusses mechanisms and therapeutic implications of osteolytic and osteoblastic bone metastases.

Entities:  

Mesh:

Year:  2006        PMID: 17062703     DOI: 10.1158/1078-0432.CCR-06-1007

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  195 in total

1.  Combined inhibition of the BMP pathway and the RANK-RANKL axis in a mixed lytic/blastic prostate cancer lesion.

Authors:  Mandeep S Virk; Farhang Alaee; Frank A Petrigliano; Osamu Sugiyama; Arion F Chatziioannou; David Stout; William C Dougall; Jay R Lieberman
Journal:  Bone       Date:  2010-11-10       Impact factor: 4.398

Review 2.  Omentum and bone marrow: how adipocyte-rich organs create tumour microenvironments conducive for metastatic progression.

Authors:  H Chkourko Gusky; J Diedrich; O A MacDougald; I Podgorski
Journal:  Obes Rev       Date:  2016-07-19       Impact factor: 9.213

Review 3.  Abnormal radiological features in a multiple myeloma patient: a case report and radiological review of myelomas.

Authors:  S Ghosh; P Wadhwa; A Kumar; Km Pai; S Seshadri; C Manohar
Journal:  Dentomaxillofac Radiol       Date:  2011-12       Impact factor: 2.419

4.  Preclinical characterization of mitochondria-targeted small molecule hsp90 inhibitors, gamitrinibs, in advanced prostate cancer.

Authors:  Byoung Heon Kang; Markus D Siegelin; Janet Plescia; Christopher M Raskett; David S Garlick; Takehiko Dohi; Jane B Lian; Gary S Stein; Lucia R Languino; Dario C Altieri
Journal:  Clin Cancer Res       Date:  2010-09-28       Impact factor: 12.531

5.  TGFβ-dependent induction of interleukin-11 and interleukin-8 involves SMAD and p38 MAPK pathways in breast tumor models with varied bone metastases potential.

Authors:  Janhavi Gupta; John Robbins; Tamas Jilling; Prem Seth
Journal:  Cancer Biol Ther       Date:  2011-02-01       Impact factor: 4.742

6.  Molecular biology and therapeutics in musculoskeletal oncology.

Authors:  Theresa A Guise; Regis O'Keefe; R Lor Randall; Richard M Terek
Journal:  J Bone Joint Surg Am       Date:  2009-03-01       Impact factor: 5.284

7.  CT-based handling and analysis of preclinical multimodality imaging data of bone metastases.

Authors:  Thomas J A Snoeks; Martin Baiker; Eric L Kaijzel; Boudewijn P F Lelieveldt; Clemens W G M Löwik
Journal:  Bonekey Rep       Date:  2012-05-09

Review 8.  Src signaling pathways in prostate cancer.

Authors:  Andreas Varkaris; Anastasia D Katsiampoura; John C Araujo; Gary E Gallick; Paul G Corn
Journal:  Cancer Metastasis Rev       Date:  2014-09       Impact factor: 9.264

Review 9.  Soluble Factors on Stage to Direct Mesenchymal Stem Cells Fate.

Authors:  Cristina Sobacchi; Eleonora Palagano; Anna Villa; Ciro Menale
Journal:  Front Bioeng Biotechnol       Date:  2017-05-17

10.  Practical method for radioactivity distribution analysis in small-animal PET cancer studies.

Authors:  Nikolai V Slavine; Peter P Antich
Journal:  Appl Radiat Isot       Date:  2008-06-14       Impact factor: 1.513

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.